These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Sarcoid-like reaction to malignancy on whole-body integrated (18)F-FDG PET/CT: prevalence and disease pattern.
    Author: Chowdhury FU, Sheerin F, Bradley KM, Gleeson FV.
    Journal: Clin Radiol; 2009 Jul; 64(7):675-81. PubMed ID: 19520211.
    Abstract:
    AIM: To evaluate the prevalence of sarcoid-like reaction to malignancy detected using integrated 2-[(18)F]-fluoro-2-deoxy-d-glucose (FDG) positron-emission tomography and computed tomography (PET/CT) in patients undergoing staging or restaging of solid-organ malignancy. MATERIALS AND METHODS: A systematic search was performed using the institutional radiology information system of 2048 consecutive PET/CT examinations performed in cancer patients at a tertiary-referral centre. Cases that were considered suspicious for sarcoid-like reaction were identified from the initial radiological report and were retrospectively reviewed by three experienced PET/CT reporters. RESULTS: Sarcoid-like reaction was initially suspected in 23 of the 2048 (1.1%) FDG PET/CT examinations, with the diagnosis confirmed histologically or by clinico-radiological follow-up in 13 of the 23 cases (57%). Sarcoid-like reaction was more commonly seen in patients undergoing FDG PET/CT for restaging of suspected recurrence rather than for primary tumour staging (77% versus 23%; p=0.05). The mean maximum standardized uptake value (SUV(max)) of confirmed hilar and mediastinal sarcoid-like reaction was 7.3 (range 3.1-13.6). Symmetric hilar uptake was demonstrated in 11 of the 13 (85%) and all 13 had additional mediastinal nodal uptake. Pulmonary uptake was seen in seven of the 13 cases (54%). Extra-thoracic involvement was present in eight of the 13 (61.5%), including nodal, splenic, and hepatic lesions. CONCLUSION: Sarcoid-like reaction was suspected in 1.1% of cancer patients at FDG PET/CT examination, with confirmation of the diagnosis in 0.6%. With the increasing use of FDG PET/CT in cancer patients, it is important to be aware of the prevalence of this uncommon, but important, disease entity and to consider this diagnosis in appropriate cases in order to avoid a false-positive interpretation of metastatic disease.
    [Abstract] [Full Text] [Related] [New Search]